^
Association details:
Biomarker:BRCA1 mutation
Cancer:Pancreatic Cancer
Drug:veliparib (ABT-888) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Excerpt:
...- Personal or known family history of a deleterious (or indeterminate) mutation in the BRCA1, BRCA2, PALBB2, or one of the FANC genes....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Excerpt:
...- BRCA1/2 mutation and a BRCA-related malignancy...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.

Published date:
03/24/2020
Excerpt:
Exploratory analyses (combined Arms): Med OS if > 4 m platinum → PARPi: 23 m (95%CI 6.5- 53.9). Med OS by BRCA: BRCA1: 14 m (8.1- 18.5); BRCA2: 20.2 m (12.3- 24.4)...GC +/- V very active in gBRCA/PALB2 mut PDAC with high RR, PFS, OS with both A, B significantly exceeding threshold RR.
Secondary therapy:
cisplatin + gemcitabine
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma

Excerpt:
The objective response rate in the BRCA+ cohort was 7 of 9 (77.8%). The median overall survival for BRCA+ patients was 23.3 months (95% confidence interval [CI], 3.8-30.2 months).
DOI:
10.1002/cncr.31218
Trial ID: